{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:16:20Z","timestamp":1791209780938,"version":"4.1.0"},"reference-count":67,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2010,11,11]],"date-time":"2010-11-11T00:00:00Z","timestamp":1289433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:p>The strong need for the development of alternative anti\u2010HIV agents is primarily due to the emergence of strain\u2010resistant viruses, the need for sustained adherence to complex treatment regimens and the toxicity of currently used antiviral drugs. This review analyzes proof of concept studies indicating that the immunomodulatory drug rapamycin (RAPA) possesses anti\u2010HIV properties both <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> that qualifies it as a potential new anti\u2010HIV drug. It represents a literature review of published studies that evaluated the <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> activity of RAPA in HIV. RAPA represses HIV\u20101 replication <jats:italic>in vitro<\/jats:italic> through different mechanisms including, but not limited, to down regulation of CCR5. In addition RAPA synergistically enhances the anti\u2010HIV activity of entry inhibitors such as vicriviroc, aplaviroc and enfuvirtide <jats:italic>in vitro<\/jats:italic>. RAPA also inhibits HIV\u20101 infection in human peripheral blood leucocytes\u2010SCID reconstituted mice. In addition, a prospective nonrandomized trial of HIV patient series receiving RAPA monotherapy after liver transplantation indicated significantly better control of HIV and hepatitis C virus (HCV) replication among patients taking RAPA monotherapy. Taken together, the evidence presented in this review suggests that RAPA may be a useful drug that should be evaluated for the prevention and treatment of HIV\u20101 infection.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2010.03735.x","type":"journal-article","created":{"date-parts":[[2010,6,23]],"date-time":"2010-06-23T12:27:20Z","timestamp":1277296040000},"page":"784-793","source":"Crossref","is-referenced-by-count":70,"title":["Potential use of rapamycin in HIV infection"],"prefix":"10.1111","volume":"70","author":[{"given":"Marco","family":"Donia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"McCubrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Bendtzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Nicoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,11,11]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.28.721"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740330903037156"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.2174\/156800908786733513"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9120(98)00045-9"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-009-0163-7"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100317"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209886"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2004.06.054"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2006.03.029"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.12.017"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2006.07.003"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1106148"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-030833"},{"key":"e_1_2_9_15_2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.6004\/jnccn.2009.0045","article-title":"New treatments for renal cell carcinoma: targeted therapies","volume":"7","author":"Saylor PJ","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.4017"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-0801"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2008.12.011"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbapap.2007.10.003"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq096"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e328331d3d0"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.2174\/157489106775244118"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e32832498d8"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(08)80048-3"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1086\/597290"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M309"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.13.2349"},{"key":"e_1_2_9_28_2","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1177\/135965350601100714","article-title":"A prospective clinical and pathological examination of injection site reactions with the HIV\u20101 fusion inhibitor enfuvirtide","volume":"11","author":"Myers SA","year":"2006","journal-title":"Antivir Ther"},{"key":"e_1_2_9_29_2","first-page":"1497","article-title":"Pharmacotherapy of HIV\u20101 infection: focus on the CCR5 antagonist maraviroc","volume":"1","author":"Latinovic O","year":"2009","journal-title":"Clin Med Ther"},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543780903357478"},{"key":"e_1_2_9_31_2","unstructured":"CohenC DeJesusE MillsA PieroneGJr KumarP RuaneP ElionR FuscoG LevyR SolomonK Erickson\u2010ViitanenS.Potent antiretroviral activity of the once\u2010daily CCR5 antagonist INCB009471 over 14 days monotherapy. 4th IAS Conference on AIDS Pathogenesis Treatment and Prevention 22\u201325 July 2007 Sydney Australia (Abstract TUAB106)."},{"key":"e_1_2_9_32_2","unstructured":"PRO 140 by IV administration in adults with HIV\u20101 infection. Sponsor: Progenics Pharmaceuticals Inc. ClinicalTrials.gov Identifier: NCT00613379. Available athttp:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00613379?term=pro\u2010140&rank=1(last accessed 29 March 2010)."},{"key":"e_1_2_9_33_2","doi-asserted-by":"publisher","DOI":"10.1086\/527327"},{"key":"e_1_2_9_34_2","unstructured":"Dose\u2010Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV\u20101 (TMB\u2010202). Sponsor: TaiMed Biologics Inc. ClinicalTrials.gov Identifier: NCT00784147. Available athttp:\/\/clinicaltrials.gov\/ct2\/show\/NCT00784147?term=HIV+Houston&recr=Open&rank=6(last accessed on 16 July 2010)."},{"key":"e_1_2_9_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.2.423-429.2004"},{"key":"e_1_2_9_36_2","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.4049\/jimmunol.163.4.2306","article-title":"Coexpression of CCR5 and IL\u20102 in human genital but not blood T cells: implications for the ontogeny of the CCR5+ Th1 phenotype","volume":"163","author":"Hladik F","year":"1999","journal-title":"J Immunol"},{"key":"e_1_2_9_37_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.9.5215"},{"key":"e_1_2_9_38_2","doi-asserted-by":"publisher","DOI":"10.1086\/315315"},{"key":"e_1_2_9_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.1.46"},{"key":"e_1_2_9_40_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0810843106"},{"key":"e_1_2_9_41_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1834278100"},{"key":"e_1_2_9_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.11.3447-3455.2002"},{"key":"e_1_2_9_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200424892"},{"key":"e_1_2_9_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/0065-2571(84)90007-4"},{"key":"e_1_2_9_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.02.199"},{"key":"e_1_2_9_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00821-07"},{"key":"e_1_2_9_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01602-06"},{"key":"e_1_2_9_48_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f02a4f"},{"key":"e_1_2_9_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2008.03780.x"},{"key":"e_1_2_9_50_2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181c7dcc0"},{"key":"e_1_2_9_51_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f37478"},{"key":"e_1_2_9_52_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.14.8742-8749.2005"},{"key":"e_1_2_9_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-009-0075-1"},{"key":"e_1_2_9_54_2","unstructured":"Rapamune package insert2002 Wyeth."},{"key":"e_1_2_9_55_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI0214522"},{"key":"e_1_2_9_56_2","doi-asserted-by":"publisher","DOI":"10.2174\/138161206776055868"},{"key":"e_1_2_9_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.10.018"},{"key":"e_1_2_9_58_2","doi-asserted-by":"publisher","DOI":"10.1089\/088922299310944"},{"key":"e_1_2_9_59_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00872-07"},{"key":"e_1_2_9_60_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200204010-00005"},{"key":"e_1_2_9_61_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0202-128"},{"key":"e_1_2_9_62_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.109.185918"},{"key":"e_1_2_9_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2009.06.186"},{"key":"e_1_2_9_64_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2007.02007.x"},{"key":"e_1_2_9_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)89026-8"},{"key":"e_1_2_9_66_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq054"},{"key":"e_1_2_9_67_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-009-0076-5"},{"key":"e_1_2_9_68_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.10.29"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2010.03735.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2010.03735.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T04:03:05Z","timestamp":1697428985000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2010.03735.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,11]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["10.1111\/j.1365-2125.2010.03735.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03735.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,11]]}}}